Syk Inhibitor CAS: 622387-85-3
MF: C18H15N3O3S
MW: 353.4
An inhibitor of FcεRI-mediated degranulation in RBL-2H3.

Syk Inhibitor (CAS 622387-85-3)

Syk Inhibitor | CAS 622387-85-3 is rated 5.0 out of 5 by 1.
  • y_2020, m_2, d_19, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204316, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 144ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Application: An inhibitor of FcεRI-mediated degranulation in RBL-2H3
CAS Number: 622387-85-3
Purity: ≥97%
Molecular Weight: 353.4
Molecular Formula: C18H15N3O3S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Syk Inhibitor is an oxindole compound that acts to effectively inhibit FcεRI-mediated degranulation in RBL-2H3. Syk Inhibitor is an inhibitor of Syk.


References

1. Lai, Justine Y Q., et al., 2003. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorganic & medicinal chemistry letters. 13(18): 3111-4. PMID: 12941345

Physical State :
Solid
Solubility :
Soluble in DMSO (5 mg/ml).
Storage :
Store at 4° C
Melting Point :
258.51° C (Predicted)
Boiling Point :
598.29° C (Predicted)
Density :
1.49 g/cm3 (Predicted)
Refractive Index :
n20D 1.73 (Predicted)
IC50 :
ATP-competitive Syk: IC50 = 14 nM; RBL-2H3: EC5050 = 313 nM (rat basophilic leukemia cell line)
pK Values :
pKa: 9.84 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
6419747
MDL Number :
MFCD07776820
SMILES :
CN1C=C(C2=CC=CC=C21)C=C3C4=C(C=CC(=C4)S(=O)(=O)N)NC3=O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Syk Inhibitor  Product Citations

See how others have used Syk Inhibitor. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 18068154  Bhavaraju, K. et al. 2008. Eur. J. Pharmacol. 580: 285-290.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 114ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Bhavaraju Bhavaraju, K. et al. (PubMed 18068154) used the Syk inhibitor as an effective positive control against potential Syk inhibitor OXSI-2. -SCBT Publication Review
Date published: 2015-07-10
  • y_2020, m_2, d_19, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204316, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 25ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.